I think a 70-80% cure rate with VX-222/Incivek/ribavirin would be a significant achievement and would be received positively. Until an interferon free, nucleotide/nucleoside regimen can prove its efficacy and safety in a large scale (several hundred patients) study of genotype 1 HCV, the investors betting on these "nukes" are taking a huge risk. Judging from the prices paid for Pharmasset and Inhibitex, they are counting 100% efficacy and no serious side effects in genotype 1 HCV. I would not expect that level of success.
It seems like all of the 7977 data that has been reported to date has had some level of "spin"...not lies, but likely not the whole picture. More like highlights. For example, as many here pointed out, the latest "100 % cure results" reported were for RVR, not SVR.
Last year, their first small clinical trial that they reported successful results from only had GT 2 and 3 patients, not the hardest to treat patients.
It seems like they have been careful to present data that can't immediately be compared head to head with Incivek (or Victrelis, for that matter). Another example of that is how one of their trials is on "interferon intolerant" patients...ie patients who wouldn't be able to complete SOC with or without Incivek.
They are doing a huge disservice to shareholders by releasing this data. The best we can hope for is 75%. the market is solely focused on headline numbers and this will be view as an uncompetitive failure. We would have been better off if they had not given a deadline for the data release and had quietly allowed it to die.